Publication Date
| In 2025 | 0 |
| Since 2024 | 0 |
| Since 2021 (last 5 years) | 0 |
| Since 2016 (last 10 years) | 0 |
| Since 2006 (last 20 years) | 1 |
Descriptor
| Adolescents | 1 |
| Behavior Modification | 1 |
| Cognitive Restructuring | 1 |
| Comparative Analysis | 1 |
| Counseling Effectiveness | 1 |
| Depression (Psychology) | 1 |
| Drug Therapy | 1 |
| Outcomes of Treatment | 1 |
| Pain | 1 |
| Patients | 1 |
| Pharmacology | 1 |
| More ▼ | |
Source
| Journal of the American… | 1 |
Author
| Casat, Charles | 1 |
| Emslie, Graham | 1 |
| Kratochvil, Christopher | 1 |
| March, John | 1 |
| Mayes, Taryn | 1 |
| McNulty, Steven | 1 |
| Pathak, Sanjeev | 1 |
| Posner, Kelly | 1 |
| Rohde, Paul | 1 |
| Silva, Susan | 1 |
| Vitiello, Benedetto | 1 |
| More ▼ | |
Publication Type
| Journal Articles | 1 |
| Reports - Research | 1 |
Education Level
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
What Works Clearinghouse Rating
Peer reviewed
Direct linkEmslie, Graham; Kratochvil, Christopher; Vitiello, Benedetto; Silva, Susan; Mayes, Taryn; McNulty, Steven; Weller, Elizabeth; Waslick, Bruce; Casat, Charles; Walkup, John; Pathak, Sanjeev; Rohde, Paul; Posner, Kelly; March, John – Journal of the American Academy of Child and Adolescent Psychiatry, 2006
Objective: To compare the rates of physical, psychiatric, and suicide-related events in adolescents with MDD treated with fluoxetine alone (FLX), cognitive-behavioral therapy (CBT), combination treatment (COMB), or placebo (PBO). Method: Safety assessments included adverse events (AEs) collected by spontaneous report, as well as systematic…
Descriptors: Safety, Patients, Adolescents, Suicide
